JP2014074046A5 - - Google Patents

Download PDF

Info

Publication number
JP2014074046A5
JP2014074046A5 JP2013255627A JP2013255627A JP2014074046A5 JP 2014074046 A5 JP2014074046 A5 JP 2014074046A5 JP 2013255627 A JP2013255627 A JP 2013255627A JP 2013255627 A JP2013255627 A JP 2013255627A JP 2014074046 A5 JP2014074046 A5 JP 2014074046A5
Authority
JP
Japan
Prior art keywords
bone resorption
resorption inhibitor
human
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013255627A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014074046A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014074046A publication Critical patent/JP2014074046A/ja
Publication of JP2014074046A5 publication Critical patent/JP2014074046A5/ja
Withdrawn legal-status Critical Current

Links

JP2013255627A 2006-12-29 2013-12-11 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 Withdrawn JP2014074046A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88264206P 2006-12-29 2006-12-29
US60/882,642 2006-12-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010509325A Division JP2010528002A (ja) 2006-12-29 2007-12-21 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016161654A Division JP2017014263A (ja) 2006-12-29 2016-08-22 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法

Publications (2)

Publication Number Publication Date
JP2014074046A JP2014074046A (ja) 2014-04-24
JP2014074046A5 true JP2014074046A5 (OSRAM) 2014-11-13

Family

ID=39584303

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010509325A Withdrawn JP2010528002A (ja) 2006-12-29 2007-12-21 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
JP2013255627A Withdrawn JP2014074046A (ja) 2006-12-29 2013-12-11 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
JP2016161654A Withdrawn JP2017014263A (ja) 2006-12-29 2016-08-22 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
JP2018179643A Pending JP2018199725A (ja) 2006-12-29 2018-09-26 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010509325A Withdrawn JP2010528002A (ja) 2006-12-29 2007-12-21 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016161654A Withdrawn JP2017014263A (ja) 2006-12-29 2016-08-22 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
JP2018179643A Pending JP2018199725A (ja) 2006-12-29 2018-09-26 Sostもしくはwiseアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法

Country Status (12)

Country Link
US (8) US8178099B2 (OSRAM)
EP (3) EP4176884A1 (OSRAM)
JP (4) JP2010528002A (OSRAM)
DK (1) DK3345607T3 (OSRAM)
ES (2) ES2666650T3 (OSRAM)
FI (1) FI3345607T3 (OSRAM)
HU (1) HUE060822T2 (OSRAM)
LT (1) LT3345607T (OSRAM)
PL (1) PL3345607T3 (OSRAM)
PT (1) PT3345607T (OSRAM)
SI (1) SI3345607T1 (OSRAM)
WO (1) WO2009131553A2 (OSRAM)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395511B1 (en) 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US7585501B2 (en) * 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
CA2578113A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8178099B2 (en) 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
CA2705879A1 (en) 2007-11-21 2009-06-04 Amgen Inc. Wise binding agents and epitopes
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
CA2795886A1 (en) * 2010-04-16 2011-10-20 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
AU2012223358A1 (en) 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
AU2012236962B2 (en) 2011-03-25 2017-05-11 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
EP2739311B9 (en) 2011-08-04 2018-09-19 Amgen Inc. Method for treating bone gap defects
EA202091676A1 (ru) 2011-12-28 2021-01-29 Эмджен Инк. Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EP2869844B2 (en) 2012-07-05 2023-06-21 UCB Pharma S.A. Treatment for bone diseases
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9770415B2 (en) * 2012-11-27 2017-09-26 Southwest Research Institute Delivery substrates from aligned polymer biomaterials for tissue repair
AU2014212081A1 (en) * 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
CA2973727A1 (en) 2015-01-16 2016-07-21 Spineovations, Inc. Method of treating spinal disk
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN106202901A (zh) * 2016-07-04 2016-12-07 奥美之路(北京)健康科技股份有限公司 骨龄远程在线判读系统
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2019154410A1 (zh) * 2018-02-12 2019-08-15 翼高生物科技有限公司 针对骨硬化蛋白的适体及其用途
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
WO2020163290A1 (en) * 2019-02-04 2020-08-13 Emory University Sclerostin inhibitors that promote bone morphogenetic protein expression
CN118307669A (zh) * 2019-07-12 2024-07-09 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
WO2024250012A2 (en) 2023-06-02 2024-12-05 33 Medical, Inc. Compositions for treatment of discogenic pain, and processes for making and using the same

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054540A1 (en) 1980-04-07 1982-06-30 BERMAN Joel d/b/a JOEL BERMAN ASSOCIATES Window shade roller assembly
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE66608T1 (de) 1984-04-30 1991-09-15 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5344654A (en) 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5324819A (en) * 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5298852A (en) * 1988-12-22 1994-03-29 Robert Bosch Gmbh Arrangement for and method of controlling a three-phase-generator in a vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5561173A (en) * 1990-06-19 1996-10-01 Carolyn M. Dry Self-repairing, reinforced matrix materials
CZ282603B6 (cs) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanizované a chimerické monoklonální protilátky
US5656593A (en) * 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
KR100259827B1 (ko) * 1991-11-04 2000-06-15 브루스 엠. 에이센, 토마스 제이 데스로저 재조합 골형태 형성 단백질 헤테로다이머, 그 조성물 및 사용방법
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
US5863537A (en) * 1992-02-19 1999-01-26 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DK0679097T3 (da) * 1993-01-12 1997-12-22 Genentech Inc TGF-Beta-præparat til fremkaldelse af knoglevækst
TW303299B (OSRAM) 1993-07-22 1997-04-21 Lilly Co Eli
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19647853A1 (de) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
US5939039A (en) 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
DE69814352T3 (de) * 1997-02-07 2009-08-13 Stryker Corp., Kalamazoo Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
JP2001524000A (ja) * 1997-04-22 2001-11-27 ワシントン リサーチ ファンデーション Trap被覆骨移植片及びプロテーゼ
US6025538A (en) * 1998-11-20 2000-02-15 Musculoskeletal Transplant Foundation Compound bone structure fabricated from allograft tissue
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
NZ528320A (en) 2001-02-23 2005-07-29 Wyeth Corp Composition for inducing cartilaginous tissue formation and maintenance comprising a non-culture expanded CD105+ cells and a BMP
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
JP2005511002A (ja) 2001-05-11 2005-04-28 ワイス 骨量変調のトランスジェニック動物モデル
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
PL222211B1 (pl) * 2001-06-26 2016-07-29 Amgen Fremont Inc Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
CN100515504C (zh) 2001-10-12 2009-07-22 美国英佛曼公司 涂层,涂布体及其制造方法
EP1446114A4 (en) * 2001-11-08 2005-05-25 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
JP2005525312A (ja) * 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
EP1467748A1 (en) * 2002-01-17 2004-10-20 Board Of Regents The University Of Texas System Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
JP3646167B2 (ja) 2002-02-19 2005-05-11 独立行政法人産業技術総合研究所 フォスフォフォリンを含む複合生体材料
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
WO2003106657A2 (en) 2002-06-14 2003-12-24 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
US20040002770A1 (en) 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
KR20040023356A (ko) 2002-09-11 2004-03-18 현대모비스 주식회사 파킹브레이크 작동시 출발제한 시스템 및 그 방법
CA2500222A1 (en) 2002-09-30 2004-04-08 Regen Biotech, Inc. Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers
JP3851602B2 (ja) * 2002-10-02 2006-11-29 ペンタックス株式会社 骨形成治療デバイス
MXPA05013115A (es) 2003-06-06 2006-05-25 Wyeth Corp Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos.
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070439A1 (en) * 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
US7189263B2 (en) * 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) * 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
EP1751185A2 (en) * 2004-05-27 2007-02-14 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
EP1804739A2 (en) * 2004-10-22 2007-07-11 The Board Of Trustees Of The University Of Illinois Hollow and porous orthopaedic or dental implant that delivers a biological agent
RU2422172C2 (ru) * 2005-01-06 2011-06-27 Бакстер Интернэшнл Инк. Дополненные матриксы для лечения переломов костей
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060198863A1 (en) 2005-03-03 2006-09-07 Musculoskeletal Transplant Foundation Ceramic composition for filling bone defects
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2006320442A (ja) 2005-05-18 2006-11-30 Toshiba Ceramics Co Ltd リン酸カルシウム系骨補填材
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
EP1933892B1 (en) 2005-09-09 2012-12-12 Wright Medical Technology, Inc. Composite bone graft substitute cement and articles produced therefrom
JP5368102B2 (ja) 2005-11-17 2013-12-18 バイオミメティック セラピューティクス, インコーポレイテッド rhPDGF−BB及び生体適合性マトリックスを用いた顎顔面骨強化
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
WO2007076062A2 (en) * 2005-12-21 2007-07-05 Wyeth Protein formulations with reduced viscosity and uses thereof
EP2094731A2 (en) * 2006-11-10 2009-09-02 UCB Pharma S.A. Anti human sclerostin antibodies
US8178099B2 (en) * 2006-12-29 2012-05-15 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
CN101646457B (zh) 2007-03-20 2013-05-01 伊莱利利公司 抗硬骨素抗体
WO2008133618A1 (en) 2007-04-27 2008-11-06 Unigene Laboratories, Inc. Methods and compositions for fostering and preserving bone growth
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
KR101962483B1 (ko) * 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6511233B2 (ja) 2014-08-28 2019-05-15 株式会社竹中工務店 柱脚部と鉄骨梁との接合構造

Similar Documents

Publication Publication Date Title
JP2014074046A5 (OSRAM)
JP2012126742A5 (OSRAM)
JP2013539454A5 (OSRAM)
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
JP2011157378A5 (OSRAM)
JP2014530215A5 (OSRAM)
JP2011528902A5 (OSRAM)
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER
RU2019140356A (ru) Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
JP2011219478A5 (OSRAM)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
MX348578B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
JP2012121878A5 (OSRAM)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
JP2015526440A5 (OSRAM)
AR082629A1 (es) Anticuerpos anti-fap (proteina de activacion fibroblastica) y metodos de uso
JP2015519052A5 (OSRAM)
JP2012522010A5 (OSRAM)
JP2014205674A5 (OSRAM)
JP2012102122A5 (OSRAM)
JP2017113019A5 (OSRAM)